|
|
|
| Clinical Efficacy of Indapamide Combined with Benazepril in the Treatment of Hypertension Complicated with Heart Failure and its Influence on the Level of Vasoactive Substances in Patients |
| CAO Xuezeng, LIU Keliang |
| Sheqi Hospital of Traditional Chinese Medicine, Sheqi Henan 473300 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of indapamide combined with benazepril in the treatment of hypertension complicated with heart failure and its influence on the level of vasoactive substances. 【Methods】A total of 108 patients with hypertension complicated with heart failure admitted to our hospital from March 2018 to January 2020 were selected and divided into observation group (indapamide combined with benazepril) and control group (hydrochlorothiazide combined with benazepril) according to the treatment method, with 54 cases in each group. The clinical efficacy, vasoactive substances [endothelin (ET), nitric oxide (NO), vasoactive peptide (Apelin), calcitonin gene-related peptide (CGRP)], cardiac function indexes [left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), N-terminal pro brain natriuretic peptide (NT-proBNP), left ventricular end diastolic diameter (LVEDD), and 6-min walking distance (6MWD)] were compared between the two groups, and the occurrence of adverse reactions was compared between the two groups. 【Results】After treatment, the clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of serum CGRP, no and Apelin in the two groups were higher than those before treatment, and ET was lower than that before treatment. The levels of serum CGRP, no and Apelin in the observation group were higher than those in the control group, and ET was lower than that in the control group (P<0.05). After treatment, LVEF and 6MWD in the two groups were higher than before treatment, LVESD, LVEDD and NT-proBNP were lower than before treatment, LVEF and 6MWD in the observation group were higher than those in the control group, LVESD, LVEDD and NT-proBNP were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Indapamide combined with benazepril has good clinical efficacy in the treatment of hypertension complicated with heart failure, which can improve cardiac function and regulate the expression of vasoactive substances.
|
|
Received: 12 May 2023
|
|
|
|
|
|
[1] 董旺黎,雷杰喻,师文涛.不同剂量沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效[J].医学临床研究,2023,40(7):976-978.
[2] 王文静.厄贝沙坦氢氯噻嗪联合金匮肾气丸治疗高血压慢性心力衰竭患者的临床效果及对NLRP3／NF-κβ通路的影响[J].医学临床研究, 2023,40(8):1225-1228.
[3] 魏丽琴.卡维地洛联合贝那普利治疗老年高血压合并心力衰竭患者的效果[J].中国民康医学,2024,36(12):8-10.
[4] 李倩.培哚普利吲达帕胺治疗高血压合并心力衰竭患者的临床疗效[J].临床合理用药杂志,2022,15(6):50-52.
[5] 彭宇明,鲁俊红.高血压病并发心力衰竭患者血管活性物质变化的临床意义[J].现代仪器与医疗,2018,24(1):82-83.
[6] 《中国高血压基层管理指南》修订委员会. 中国高血压基层管理指南(2014年修订版)[J].中华高血压杂志,2015,23(1):24-43.
[7] 国家卫生计生委合理用药专家委员会中国药师协会. 心力衰竭合理用药指南[J].中国医学前沿杂志(电子版),2016,8(9):19-66.
[8] 葛均波,徐永健. 内科学[M]. 8版.北京:人民卫生出版社,2013:164-166.
[9] 王粉鱼.贝那普利联合吲达帕胺治疗高血压合并心力衰竭的效果评价[J].中国药物与临床,2017,17(8):1221-1222.
[10] 唐雪梅,徐岩鹰,万成涛.丹参酮ⅡA磺酸钠注射液联合美托洛尔对老年高血压合并心力衰竭患者的疗效[J].心血管康复医学杂志,2021,30(6):699-703.
[11] 韩艳丽,冯爽,金勇.贝那普利联合吲达帕胺治疗高血压合并心力衰竭患者的临床疗效[J].中国药物经济学,2016,11(3):43-44.
[12] 上官黎明,张海誉.贝那普利片联合美托洛尔片对高血压合并心力衰竭患者心功能及血 GMP-140、CT-1水平的影响[J].心血管病防治知识,2023,13(9):31-33.
[13] 李霞.厄贝沙坦氢氯噻嗪联合甲状腺素治疗老年重症慢性心衰的疗效[J].中国老年保健医学,2019,17(5):75-77.
[14] 宋昆鹏,石海莉,陈珂,等.大株红景天注射液联合贝那普利治疗高血压伴心力衰竭的疗效及对血管活性物质的影响[J].中国循证心血管医学杂志,2020,12(3):374-376.
[15] 张增林.吲达帕胺联合培哚普利治疗高血压合并心力衰竭的疗效分析[J].世界最新医学信息文摘,2019,19(54):114-115. |
|
|
|
2024, Vol. 41 
